BioCentury
ARTICLE | Clinical News

NKTR-102: Phase III ongoing

January 20, 2014 8:00 AM UTC

Nektar said an independent DMC recommended continuation of the open-label, international Phase III BEACON trial of NKTR-102 following a planned interim efficacy analysis which included 50% of patient ...